# Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

> **NCT04571437** · PHASE2 · UNKNOWN · sponsor: **Cairo University** · enrollment: 204 (estimated)

## Conditions studied

- Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT04571437
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-04-30
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571437, "Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04571437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*